Recent evidence from a large Scandinavian cohort study indicates that empagliflozin and dapagliflozin offer comparable cardiovascular and renal efficacy, with similar risks of major cardiovascular events, heart failure (HF) hospitalizations, and serious renal events, as well as no significant differences in overall mortality or diabetic ketoacidosis.1 More recently, their potential benefits in acute settings, such as after acute myocardial infarction (AMI), have attracted increasing interest, potentially expanding the therapeutic indications for SGLT2 inhibitors in cardiovascular care.2 This evidence concerns the gene SLC5A2 and myocardial infarction.